Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Paul G. Toomey, Sharona Ross, Shalin Shah, Alexander S. Rosemurgy
Background: Survival for patients with pancreatic adenocarcinoma continues to be poor. Patients with pancreatic adenocarcinoma that is deemed borderline resectable have imaging that shows disease involvement of the portal vein and/or superior mesenteric vein…
Mongia Achour, Dorra Zeghal
In spite of preventive measures such as Papanicolaou cervical cytological analysis and, more recently, vaccination against HPV infection, cancer of the uterine cervix continues to be one of the most frequent causes of mortality among women worldwide, particul…
Michael Back, Elizabeth Back, Marina Kastelan, Helen Wheeler
Cognitive deficits related to tumour or treatment are estimated to be present in the majority of patients diagnosed with a primary brain tumour, with a large variation based on tumour site, extent, and grade, as well as nature of intervention. These deficits…
James Bracken, Tamara Ghanem, Abdul Kasem, Wen G. Jiang, Kefah Mokbel
Introduction: Downstream of tyrosine kinase 7 (DOK-7) is a member of the DOK family, which ha s been associated with the development and progression of various humancancers. Previously, identification of CpG hypermethylation in DOK-7 promoter was identified i…
Jeremiah T. Martin, Brittany A. Zwischenberger, Thomas Fabian
Malignant pleural mesothelioma is a rare primary tumor rising from the pleura and is associated with exposure to asbestos fibers. Mesothelioma is a locally aggressive disease that usually presents at an advanced stage and has a median overall survival of 1 ye…
Ahmed El Bastawisy, Abeer Bahnasy, Amany El-Zeiny, Samar Farid
Background: UGT1A1*28 polymorphism is associated with neutropenia and diarrhea in previous reports, while this study tried to investigate correlation with other toxicities like vomiting. Patients and Methods: This is a prospective case control study including…
Kent Yip, Vicky Goh, Jane Gregory, Ian Simcock, J. James Stirling, N. Jane Taylor, Robert Kozarski, Andrew Mitchell, Sam Bosopem, Gavin Halbert, Roberto Alonzi, David Miles, Peter Hoskin
Purpose: To assess the baseline variation in global renal and tumour blood flow, blood volume and extraction fraction, and changes in these parameters related to the acute physiological effects of a single dose of a non selec tive inhibitor of nitric oxide sy…
Thomas Bauernhofer, Helmut Samonigg, Peter Regitnik, Werner Weitzer, Brigitte Lileg, Günter Waxenecker, Susanne Wiederkum, Manuela Kainer, Manfred Schuster, Hans Loibner, Markus Fido, Ralf Kircheis, Andreas Nechansky
Purpose: Investigation of safety and tolerability as well as therapeutic efficacy of the LeY specific humanized mAb MB311 in cancer pts with malignant effusions in a Phase II clinical trial. Experimental Design: An openlabel, single treatment arm, uncontrolle…
Daniela Musio, Francesca De Felice, Cristina Bigelli, Nadia Bulzonetti, Roberta Guarnaccia, Mario Tombolini, Giovanni Ruoppolo, Marco de Vincentiis, Vincenzo Tombolini
Background: This is a retrospective study on a group of patients with early glottic carcinoma, treated with curative radiotherapy. The aim of the study is to assess voice quality after treatment. We also evaluated local recurrence, overall survival, disease f…
Shinichi Yamauchi, Satoru Iida, Megumi Ishiguro, Toshiaki Ishikawa, Hiroyuki Uetake, Kenichi Sugihara
Platelet-derived growth factors (PDGFs) are known to be associated with tumor growth and angiogenesis through their activation of the receptor tyrosine kinases, PDGF receptors alpha and beta. Several studies revealed the participation of the PDGF family in co…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).